CEO Josh Riggs discusses the regulatory pathway for their assay, using the de novo pathway with an expected 7-month timeline for FDA approval. They plan to submit data by year-end and have the product approved by mid-2026.
Read MoreDid you find this insightful?
Amazing
Bad
Just Okay